RXRX - RECURSION PHARMACEUTICALS, INC.

3.64
0.100   2.747%

Share volume: 16,101,964
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$3.54
0.10
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 25%
Liquidity 58%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.28%
1 Month
2.25%
3 Months
-22.72%
6 Months
-21.04%
1 Year
-44.68%
2 Year
-69.44%
Key data
Stock price
$3.64
P/E Ratio 
0.00
DAY RANGE
$3.53 - $3.76
EPS 
-$1.59
52 WEEK RANGE
$2.98 - $7.18
52 WEEK CHANGE
-$41.67
MARKET CAP 
2.129 B
YIELD 
N/A
SHARES OUTSTANDING 
527.398 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
3.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$18,645,691
AVERAGE 30 VOLUME 
$21,719,537
Company detail
CEO: Chistopher C. Gibson
Region: US
Website: recursion.com
Employees: 400
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.

Recent news